1,621
Views
11
CrossRef citations to date
0
Altmetric
Addiction Medicine

Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder

ORCID Icon, &
Pages 893-901 | Received 20 Mar 2017, Accepted 07 Jun 2017, Published online: 22 Jun 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sierra Castedo de Martell, Lori Holleran Steiker, Andrew Springer, Jeffery Jones, Emily Eisenhart & H. Shelton Brown III. (2022) The cost-effectiveness of collegiate recovery programs. Journal of American College Health 0:0, pages 1-12.
Read now
Suprit Parida, Kathleen M. Carroll, Ismene L. Petrakis & Mehmet Sofuoglu. (2019) Buprenorphine treatment for opioid use disorder: recent progress. Expert Review of Clinical Pharmacology 12:8, pages 791-803.
Read now

Articles from other publishers (9)

Pietro Scurti, Marco Nunzi, Claudio Leonardi, Claudio Pierlorenzi, Roberta Marenzi & Vincenzo Lamartora. (2023) The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews. Frontiers in Psychiatry 14.
Crossref
R. Ling, B. White, J. Roberts, M. Cretikos, M. V. Howard, P. S. Haber, N. Lintzeris, P. Reeves, A. J. Dunlop & A. Searles. (2022) Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model. BMC Health Services Research 22:1.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 101 234 .
Magdalena Cerdá, Mohammad S Jalali, Ava D Hamilton, Catherine DiGennaro, Ayaz Hyder, Julian Santaella-Tenorio, Navdep Kaur, Christina Wang & Katherine M Keyes. (2021) A Systematic Review of Simulation Models to Track and Address the Opioid Crisis. Epidemiologic Reviews 43:1, pages 147-165.
Crossref
Vicki Osborne, Miranda Davies, Debabrata Roy, Francesco Tescione & Saad A W Shakir. (2020) Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management. BMJ Evidence-Based Medicine 25:6, pages 199-205.
Crossref
Marco Riglietta. (2020) Buprenorphine implants: review of literature evidence and impacts on subjects with opioid use disorders. Minerva Psichiatrica 61:1 Suppl. 2.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 135 .
Fernanda P. Pons-Faudoa, Andrea Ballerini, Jason Sakamoto & Alessandro Grattoni. (2019) Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomedical Microdevices 21:2.
Crossref
Christopher J. Shephard & Aaron D. Drovandi. (2019) Sustained‐release subdermal buprenorphine implants: the future of opioid use disorder management?. Journal of Pharmacy Practice and Research 49:1, pages 41-49.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.